The Age of Cyclic Dinucleotide Vaccine Adjuvants
Open Access
- 13 August 2020
- Vol. 8 (3), 453
- https://doi.org/10.3390/vaccines8030453
Abstract
As prophylactic vaccine adjuvants for infectious diseases, cyclic dinucleotides (CDNs) induce safe, potent, long-lasting humoral and cellular memory responses in the systemic and mucosal compartments. As therapeutic cancer vaccine adjuvants, CDNs induce potent anti-tumor immunity, including cytotoxic T cells and NK cells activation that achieve durable regression in multiple mouse models of tumors. Clinical trials are ongoing to fulfill the promise of CDNs (ClinicalTrials.gov: NCT02675439, NCT03010176, NCT03172936, and NCT03937141). However, in October 2018, the first clinical data with Merck’s CDN MK-1454 showed zero activity as a monotherapy in patients with solid tumors or lymphomas (NCT03010176). Lately, the clinical trial from Aduro’s CDN ADU-S100 monotherapy was also disappointing (NCT03172936). The emerging hurdle in CDN vaccine development calls for a timely re-evaluation of our understanding on CDN vaccine adjuvants. Here, we review the status of CDN vaccine adjuvant research, including their superior adjuvant activities, in vivo mode of action, and confounding factors that affect their efficacy in humans. Lastly, we discuss the strategies to overcome the hurdle and advance promising CDN adjuvants in humans.This publication has 108 references indexed in Scilit:
- Single Nucleotide Polymorphisms of Human STING Can Affect Innate Immune Response to Cyclic DinucleotidesPLOS ONE, 2013
- STING is a direct innate immune sensor of cyclic di-GMPNature, 2011
- MPYS Is Required for IFN Response Factor 3 Activation and Type I IFN Production in the Response of Cultured Phagocytes to Bacterial Second Messengers Cyclic-di-AMP and Cyclic-di-GMPThe Journal of Immunology, 2011
- Bis-(3′,5′)-cyclic dimeric adenosine monophosphate: Strong Th1/Th2/Th17 promoting mucosal adjuvantVaccine, 2011
- TheN-Ethyl-N-Nitrosourea-InducedGoldenticketMouse Mutant Reveals an Essential Function ofStingin theIn VivoInterferon Response toListeria monocytogenesand Cyclic DinucleotidesInfection and Immunity, 2011
- Identification and characterization of a loss-of-function human MPYS variantGenes & Immunity, 2011
- A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMPThe Journal of Experimental Medicine, 2009
- Towards an understanding of the adjuvant action of aluminiumNature Reviews Immunology, 2009
- c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infectionVaccine, 2008
- Cyclic Di-GMP Stimulates Protective Innate Immunity in Bacterial PneumoniaInfection and Immunity, 2007